Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

201
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
201
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

195
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
195
Electrical Current01:10

Electrical Current

7.2K
Electrical current is defined as the rate at which charge flows. When there is a large current present, such as that used to run a refrigerator, a large amount of charge moves through the wire in a small amount of time. If the current is small, such as that used to operate a handheld calculator, a small amount of charge moves through the circuit over a long period of time. The SI unit for current is the ampere (A), named for the French physicist André-Marie Ampère (1775–1836).
7.2K
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

186
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
186
Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

522
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
522
Sustainable Development01:43

Sustainable Development

15.1K
As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
15.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric Phthiriasis Palpebrarum: A French Multicentric Retrospective Study of 20 Cases.

Journal of pediatrics. Clinical practice·2026
Same author

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026
Same author

Quick assessment of quality-of-life in itch: An exploratory validation of the 5-item pruritus life quality.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Impact of atopic dermatitis on education and career choices: the Scars of Life international study.

The Journal of investigative dermatology·2026
Same author

Perceived Stress, Illness and Stigma in Patients with Alopecia Areata.

Acta dermato-venereologica·2026
Same author

The Long-Term Impact of Childhood and Adolescent Atopic Dermatitis on Physical and Psychosocial Well-Being: Scars of Life project.

Clinical and experimental dermatology·2026

Related Experiment Video

Updated: Jan 31, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.2K

Current pharmaceutical developments in atopic dermatitis.

Laurent Misery1, Flavien Huet1, Olivier Gouin2

  • 1University of Brest, LIEN, F-29200 Brest, France; University Hospital of Brest, Department of Dermatology, Brest, France.

Current Opinion in Pharmacology
|January 6, 2019
PubMed
Summary

New treatments for atopic dermatitis (AD) are emerging, targeting cytokines and neurotransmitters. While cytokine antagonists and JAK inhibitors show promise for itch relief, placebo effects complicate evaluating other treatments.

More Related Videos

Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface
07:00

Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface

Published on: August 11, 2017

8.7K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.0K

Related Experiment Videos

Last Updated: Jan 31, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.2K
Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface
07:00

Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface

Published on: August 11, 2017

8.7K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.0K

Area of Science:

  • Immunology and neurobiology research
  • Dermatology and atopic diseases
  • Pharmacological research

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin condition often starting in childhood.
  • AD frequently co-occurs with asthma and allergic rhino-conjunctivitis.
  • Recent advances mirror the treatment evolution seen in psoriasis.

Purpose of the Study:

  • To review emerging treatments for atopic dermatitis.
  • To highlight novel therapeutic targets including cytokines and neurotransmitters.
  • To assess the efficacy of new AD treatments, particularly for pruritus.

Main Methods:

  • Review of current immunological and neurobiological research in AD.
  • Analysis of ongoing clinical trials for novel AD therapeutics.
  • Evaluation of drug targets such as cytokines (IL-4, IL-13, IL-31, TSLP), neurotransmitters, phosphodiesterase-4, and Jak/Stat pathways.

Main Results:

  • Several novel treatments targeting specific cytokines and neurotransmitter pathways are under development.
  • Cytokine antagonists and JAK inhibitors demonstrate significant efficacy in reducing pruritus.
  • Distinguishing drug effects from placebo is challenging for some treatments due to high placebo response in itch.

Conclusions:

  • A new era of targeted therapies for atopic dermatitis is approaching.
  • Emerging treatments offer potential for improved management of AD, especially concerning itch.
  • Further research is needed to fully elucidate the efficacy of various new drug classes in AD treatment.